Drugs / SARS-CoV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00533741 | ? → Jan 2012 | severe acute respiratory syndrome | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-03-27 | ExeVir Bio BV | Results Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that bind a conserved membrane proximal epitope of the spike exevir.com ↗
Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that bind a conserved membrane proximal epitope of the spike |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-03-27 | ExeVir Bio BV | Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that bind a conserved membrane proximal epitope of the spike exevir.com ↗ |
| 2021-09-22 | Vicore Pharma AB | Vicore obtains SARS coronavirus patent for C21 in the USA vicorepharma.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SARS-CoV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00533741 ↗ |
| Known as | SARS Coronavirus | “Phase I, Double-Blinded, Placebo-Controlled Dosage Escalation Study of the Safety and Immunogenicity of Adjuvanted and Non-Adjuvanted Inactivated SARS Coronavirus (SARS-CoV)...” NCT00533741 ↗ |
| Modality | Vaccine | “Whole-virus vaccine, grown in certified Vero cells and doubly inactivated by treatment with formalin and ultraviolet light (UV).” NCT00533741 ↗ |
| Route | Intramuscular | “administered by the Intramuscular Route” NCT00533741 ↗ |